Is Sanofi-Aventis After Bristol-Myers?
Speculation is mounting that the long-rumored merger between Franco-German drugmaker Sanofi-Aventis and New York-based Bristol-Myers Squibb may soon be reality. If true, the deal will enable Sanofi to vault past Pfizer (PFE) and Britain's GlaxoSmithKline (GSK) to become the world's largest drugmaker, with combined annual revenues of nearly $55 billion. Neither company is commenting. But a recent report in French financial newsletter La Lettre de l'Expansion claims the two companies have already signed a pre-merger agreement.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Puerto Rico Faces Hurricane Maria After Irma’s $1 Billion Damage
- The World’s Biggest Wealth Fund Hits $1 Trillion
- Finland’s Welfare State Has a Massive Baby Problem
- Equifax Suffered a Hack Almost Five Months Earlier Than the Date It Disclosed
- Toys ‘R’ Us Collapses Into Bankruptcy Thanks to Crushing Debt